Loading clinical trials...
Loading clinical trials...
Phase Ib/II Trial Of Iberdomide-Combinations In Patients With Positive Minimal Residual Disease (>10-5) After Autologous Hematopoietic Cell Transplantation In The Upfront Management Of Patients With Multiple Myeloma
Conditions
Interventions
Iberdomide
Daratumumab
+2 more
Locations
6
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Duke University
Durham, North Carolina, United States
Ohio State University Medical College
Columbus, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
Vanderbilt University Medical College
Nashville, Tennessee, United States
University of Wisconsin
Madison, Wisconsin, United States
Start Date
January 18, 2023
Primary Completion Date
April 1, 2026
Completion Date
October 1, 2026
Last Updated
April 15, 2026
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06057402
NCT06870760
Lead Sponsor
University of Alabama at Birmingham
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions